患者来源异种移植物的前景：老鼠和人类的最佳计划。
The promise of patient-derived xenografts: the best laid plans of mice and men.
机构信息
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Clin Cancer Res. 2012 Oct 1;18(19):5160-2. doi: 10.1158/1078-0432.CCR-12-2408. Epub 2012 Aug 21.
Abstract
Compared with xenografts from previously established cell lines, patient-derived xenografts may more faithfully recapitulate the molecular diversity, cellular heterogeneity, and histology seen in patient tumors, although other limitations of murine models remain. The ability of these models to inform clinical development and answer mechanistic questions will determine their ultimate use.
摘要
与先前建立的细胞系的异种移植物相比，患者来源的异种移植物可能更能真实地再现患者肿瘤中所见的分子多样性、细胞异质性和组织学，尽管仍然存在其他啮齿动物模型的局限性。这些模型在告知临床开发和回答机制问题方面的能力将决定它们的最终用途。
相似文献
1
The promise of patient-derived xenografts: the best laid plans of mice and men.患者来源异种移植物的前景：老鼠和人类的最佳计划。
Clin Cancer Res. 2012 Oct 1;18(19):5160-2. doi: 10.1158/1078-0432.CCR-12-2408. Epub 2012 Aug 21.
2
Modeling of Patient-Derived Xenografts in Colorectal Cancer.结直肠癌患者来源异种移植模型
Mol Cancer Ther. 2017 Jul;16(7):1435-1442. doi: 10.1158/1535-7163.MCT-16-0721. Epub 2017 May 3.
3
Patient-derived bladder cancer xenografts: a systematic review.患者来源的膀胱癌异种移植：系统评价。
Transl Res. 2015 Oct;166(4):324-31. doi: 10.1016/j.trsl.2015.02.001. Epub 2015 Feb 12.
4
Tumor-derived CXCL5 promotes 5-fluorouracil resistance in colorectal cancer cells via p21 downregulation.肿瘤来源的CXCL5通过下调p21促进结肠癌细胞对5-氟尿嘧啶的耐药性。
Med Oncol. 2025 Jun 13;42(7):257. doi: 10.1007/s12032-025-02801-6.
5
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.伊立替康、奥沙利铂和雷替曲塞用于治疗晚期结直肠癌：系统评价与经济学评估
Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. doi: 10.3310/hta12150.
6
A systematic overview of chemotherapy effects in colorectal cancer.结直肠癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):282-308. doi: 10.1080/02841860151116367.
7
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.BRAF 抑制剂 vemurafenib 在 BRAF 突变型结直肠癌的临床前模型中的抗肿瘤活性。
Cancer Res. 2012 Feb 1;72(3):779-89. doi: 10.1158/0008-5472.CAN-11-2941. Epub 2011 Dec 16.
8
A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries.一种新型的食管腺癌患者来源的原位异种移植模型为转化研究提供了一个平台。
Dis Model Mech. 2019 Dec 17;12(12):dmm041004. doi: 10.1242/dmm.041004.
9
Deep learning-driven drug response prediction and mechanistic insights in cancer genomics.深度学习驱动的癌症基因组学中的药物反应预测及机制洞察
Sci Rep. 2025 Jul 1;15(1):20824. doi: 10.1038/s41598-025-91571-2.
10
Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.成骨肉瘤 PDX 衍生细胞系模型用于临床前药物评价，通过基因组靶向方法证明达昔昔布抑制转移。
Clin Cancer Res. 2024 Feb 16;30(4):849-864. doi: 10.1158/1078-0432.CCR-23-0873.
引用本文的文献
1
The role of DNA methylation and demethylation in bladder cancer: a focus on therapeutic strategies.DNA甲基化与去甲基化在膀胱癌中的作用：聚焦治疗策略
Front Oncol. 2025 Jun 26;15:1567242. doi: 10.3389/fonc.2025.1567242. eCollection 2025.
2
Novel mixed cancer-cell models designed to capture inter-patient tumor heterogeneity for accurate evaluation of drug combinations.新型混合癌细胞模型旨在捕捉患者间肿瘤异质性，以准确评估联合用药。
Res Sq. 2025 May 16:rs.3.rs-6590535. doi: 10.21203/rs.3.rs-6590535/v1.
3
A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.一个患者来源的T细胞淋巴瘤生物样本库揭示了致病机制和宿主相关的治疗弱点。
Cell Rep Med. 2025 Apr 15;6(4):102029. doi: 10.1016/j.xcrm.2025.102029. Epub 2025 Mar 26.
4
Opportunities and challenges for patient-derived models of brain tumors in functional precision medicine.功能性精准医学中脑肿瘤患者衍生模型的机遇与挑战
NPJ Precis Oncol. 2025 Feb 14;9(1):47. doi: 10.1038/s41698-025-00832-w.
5
The role of mesenchymal cells in cholangiocarcinoma.间充质细胞在胆管癌中的作用。
Dis Model Mech. 2024 Dec 1;17(12). doi: 10.1242/dmm.050716. Epub 2024 Dec 13.
6
Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives.肿瘤转移的机制洞察与治疗干预：最新进展与展望
Signal Transduct Target Ther. 2024 Aug 2;9(1):192. doi: 10.1038/s41392-024-01885-2.
7
Correspondence to editorial on "UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL".致关于“UBE2S通过增强VHL的非E3酶依赖性多聚泛素化促进肝细胞癌糖酵解”的社论的信函。
Clin Mol Hepatol. 2025 Jan;31(1):e58-e60. doi: 10.3350/cmh.2024.0590. Epub 2024 Jul 29.
8
Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.用于前列腺癌转化研究和药物开发的患者来源异种移植模型。
Methods Mol Biol. 2024;2806:153-185. doi: 10.1007/978-1-0716-3858-3_12.
9
Discovery of a nitroaromatic nannocystin with potent in vivo anticancer activity against colorectal cancer by targeting AKT1.发现一种硝基芳香族纳曲酮，通过靶向 AKT1 对结直肠癌具有强大的体内抗癌活性。
Acta Pharmacol Sin. 2024 May;45(5):1044-1059. doi: 10.1038/s41401-024-01231-w. Epub 2024 Feb 7.
10
Challenges and Prospects of Patient-Derived Xenografts for Cancer Research.用于癌症研究的患者来源异种移植模型的挑战与前景
Cancers (Basel). 2023 Aug 31;15(17):4352. doi: 10.3390/cancers15174352.
本文引用的文献
1
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.对代表人类结直肠癌临床异质性的大型患者来源肿瘤异种移植模型进行表征。
Clin Cancer Res. 2012 Oct 1;18(19):5314-28. doi: 10.1158/1078-0432.CCR-12-0372. Epub 2012 Jul 23.
2
3
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes.从患有乳腺癌的女性身上获得的肿瘤移植物真实地反映了肿瘤的病理、生长、转移和疾病结果。
Nat Med. 2011 Oct 23;17(11):1514-20. doi: 10.1038/nm.2454.
4
Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy.新辅助治疗后建立的人胰腺腺癌直接异种移植瘤的分子谱分析。
Ann Surg Oncol. 2012 Jul;19 Suppl 3(0 3):S395-403. doi: 10.1245/s10434-011-1839-4. Epub 2011 Jun 24.
5
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer.个体化肿瘤移植指导下的晚期癌症患者治疗的初步临床研究。
Mol Cancer Ther. 2011 Aug;10(8):1311-6. doi: 10.1158/1535-7163.MCT-11-0233. Epub 2011 Jun 14.
6
PI-3-Kinase inhibitors in colorectal cancer.PI-3-Kinase 抑制剂在结直肠癌中的应用。
Curr Cancer Drug Targets. 2011 Feb;11(2):190-8. doi: 10.2174/156800911794328448.
7
Finding the tumor copycat. Therapy fails, patients don't.寻找肿瘤模仿者。治疗可能失败，但患者不会放弃。
Nat Med. 2010 Sep;16(9):974-5. doi: 10.1038/nm0910-974.
8
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice.在免疫缺陷小鼠中生成原位和异位人胰腺癌细胞异种移植物。
Nat Protoc. 2009;4(11):1670-80. doi: 10.1038/nprot.2009.171. Epub 2009 Oct 29.
9
The use of xenograft models for the selection of cancer treatments with the EGFR as an example.以表皮生长因子受体（EGFR）为例，异种移植模型在癌症治疗选择中的应用。
Crit Rev Oncol Hematol. 2008 Mar;65(3):200-11. doi: 10.1016/j.critrevonc.2007.10.003.
10
Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas.早期传代异种移植结肠癌中抗癌药物反应及分子标志物表达
Eur J Cancer. 2004 Jan;40(2):298-307. doi: 10.1016/j.ejca.2003.10.011.
Zotero 插件